Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL006 in Advanced Solid Tumors
NCT06621615Phase 1Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of CVL006 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Convalife Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
CVL006
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06621615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621615.